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Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489S166Results: Culture of human chondrocytes in high glucose (30 mM) for up
to 48h had no effect on the viability of either primary chondrocytes or
C28/I2 chondrocytic cells. Exposure to high glucose (30 mM) for 24h
signiﬁcantly increased IL-1b and TNF-amRNA levels (196.833.6%, P ¼
0.0066 and 285.454.5%, P ¼ 0.0045, respectively). On the other hand,
LC3-II levels, as well as the ratio LC3-II/LC3-I, were signiﬁcantly reduced
by culture of C28/I2 cells in high glucose for 24h, remaining low at 48h,
either in the presence or absence of chloroquine. This indicates that
LC3-II synthesis was decreased relative to cells maintained in regular
glucose medium. Culture in mannitol-containing medium (20 mM in
medium containing 10 mM glucose) for up to 48h had no signiﬁcant
effect on LC3-I and II levels.
Conclusions: Hyperglycemia-like glucose concentrations are sufﬁcient
to induce inﬂammatory responses and impair autophagy in human
chondrocytes which can contribute to the development and pro-
gression of OA in patients with DM and other conditions associatedwith
impaired glucose homeostasis.
This work was supported by FEDER and the Portuguese Foundation for
Science and Technology (FCT) grants PEst-C/SAU/LA0001/2011 and
PTDC/EME TME/113039/2009 and PhD fellowships SFRH/BD/47470/
2008 and SFRH/BD/78188/2011.
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MCPIP1 REGULATES THE EXPRESSION OF INTERLEUKIN-6 IN
HUMAN OSTEOARTHRITIS CHONDROCYTES
M.S. Makki, A. Haseeb, T.M. Haqqi. Northeast Ohio Med. Univ.,
Rootstown, OH, USA
Purpose: Post-transcriptional regulation of cytokine expression is
important s for maintaining tissue integrity. MCPIP1 (also known as
ZC3H12A) was identiﬁed as a novel protein, which harbors CCCH-type
zinc-ﬁnger domain and a PIN-like RNase domain. MCPIP1 destabilizes
inﬂammatory cytokines mRNAs via their 3’ UTR. Osteoarthritis (OA)
affects 27 million Americans and is a leading cause of disability
worldwide in elderly. IL-6 has recently gained attention because of its
high levels in synovial ﬂuid and ability to induce MMP-13 in OA. In the
present study we determined whether MCPIP1 regulates IL-6 expres-
sion in human OA chondrocytes.
Methods Human cartilage samples were obtained from OA patients
who underwent total joint arthroplasty and chondrocytes were pre-
pared by the enzymatic digestion. For gene expression analysis total
RNAwas isolated from cultured primary chondrocytes or from damaged
or smooth OA cartilage using RNeasy mini kit (Qiagen). RNA ﬂuorescent
in-situ hybridization (ISH) for IL-6 and MCPIP1 expression was per-
formed using RNAScope (ACD, CA) according to the instructions. Wild
type or mutant MCPIP1 was overexpressed in chondrocytes transfected
with the cDNA constructs using Amaxa. Knockdown experiments were
performed using Trisilencer-27 human siRNAs (Origene). For RNA
immunoprecipitation, chondrocytes were stimulated with IL-1b (1ng/
ml) for 12 h and then treated with 1% formaldehyde to cross link pro-
tein-RNA complexes. After sonication, extracts were centrifuged and
lysates were incubated overnight with isotype control IgG or with anti-
MCPIP1 antibody (Origene). After multiple stringent washes and
reverse cross-linking RNA was puriﬁed using RNeasy mini kit. Expres-
sion of IL-6 and MCPIP1 was assessed using TaqMan assays (Applied
Biosystems, Carlsbad, CA). Expression of IL-6 targeting miRNAs in
chondrocytes was quantiﬁed by TaqMan assays.
Results: High levels of IL-6 mRNA were induced in chondrocytes
stimulated with IL-1b in a time dependent manner and peaked at 8h
post-stimulation and then declined. On the other hand, expression of
MCPIP1 mRNA peaked at 6h post-stimulation with IL-1b. Using multi-
plex RNA ﬂuorescent ISH, expression of both IL-6 and MCPIP1 mRNA in
IL-1b stimulated human chondrocytes, also showed that IL-6 mRNA
expression was relatively high compared to MCPIP1 mRNA expression
with distinct speckle patterns. Both IL-6 and MCPIP1 mRNAs were
localized in the nuclei as well as in the cytoplasm. Overexpression of
wild typeMCPIP1, but not mutant MCPIP1, reduced the expression of IL-
6 mRNA. Importantly siRNA-mediated knockdown of MCPIP1 elevated
the IL-6 mRNA expression in human chondrocytes. Interestingly,
alteration in gene expression of other OA markers (MMP3, ACAN or
COL10A1) was not observed, suggesting that these are not regulated by
MCPIP1. To conﬁrm the binding of MCPIP1 with IL-6 mRNA, RNA
immunoprecipitation was performed using anti-MCPIP1 antibody.
TaqMan analysis of the immunoprecipitated mRNAs showed that anti-
MCPIP1 antibody pulled down larger amount of IL-6 mRNA than controlIgG antibody did. To investigate whether there is any indirect effect on
IL-6 mRNA stability upon knockdown of MCPIP1 through miRNAs, we
investigated expression of several reported IL-6 targeting miRNAs (mir-
26a, mir-26b, mir-142-3p andmir-146a). No signiﬁcant difference in the
expression of assayedmiRNAswas observed. Finally, we determined the
expression of MCPIP1 in damaged and smooth cartilage of OA (n¼ 9). In
majority of samples (n ¼ 7) MCPIP1 expression was down-regulated in
damaged cartilage compared to smooth cartilage, suggesting lower
expression of MCPIP1 may be contributing to the excessive expression
of IL-6 in OA.
Conclusions: Expression of MCPIP1 in human cartilage and chon-
drocytes is shown for the ﬁrst time. Differential expression of MCPIP1 in
damaged and smooth cartilage and its stimulation by IL-1b, a pro-
inﬂammatory cytokine implicated in the pathogenesis of the disease,
suggest a role for MCPIP1 in OA. Interestingly binding of MCPIP1 protein
with IL-6 mRNA indicated that enzymatic activity of MCPIP1 is impor-
tant for the regulation of IL-6mRNA expression in human chondrocytes.
Moreover, expression of several reported IL-6 targeting miRNAs was
unchanged upon MCPIP1 knockdown suggesting that MCPIP1 exert its
effect directly on IL-6 mRNA. Furthermore, we also showed down-
regulation of MCPIP1 expression in damaged cartilage compare to
smooth cartilage suggesting its contribution in the up-regulation of IL-6
and related OA pathophysiology. Taken together, our data suggests that
MCPIP1, a novel RNA modifying enzyme, may be an important player in
OA pathogenesis.
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DNA OXIDATIVE DAMAGE AND ITS REPAIR ENZYME (OGG1) IN
OSTEOARTHRITIC CHONDROCYTES
K. Yudoh y, R. Karasawa y, N. Yui z, H. Yoshioka z. y Institiute of Med. Sci.,
St. Marianna Univ. Sch. of Med., Kawasaki City, Japan; zDept. of Sports
Med., St. Marianna Univ. Sch. of Med., Kawasaki City, Japan
Background: It is well known that chondrocytes produce excess
amounts of reactive oxygen species (ROS) as well as proinﬂammatory
cytokines and chemokines in response to mechanical and chemical
stresses. Studies have provided ample conﬁrmation of the generation of
ROS and the depletion of cellular antioxidants in degenerated articular
cartilage. 8-Oxoguanine, an oxidized form of guanine, is produced by
ROS in large amounts in both DNA and nucleotide pools. 8-Oxoguanine
is a major causative lesion for mutagenesis by ROS, since it can form a
stable base pair with adenine as well as with cytosine during DNA
replication. 8-Oxoguanine DNA glycosylase (Ogg1) repairs 8-oxogua-
nine, one of the most abundant DNA adducts caused by oxygen free
radicals. Ogg1 is thought to protect against activation of the intrinsic
apoptotic pathway in response to oxidative stress by augmenting DNA
repair in a variety of cells. We postulated that depletion of cellular
antioxidant, Ogg1, in osteoarthritic chondrocytes may participate in the
degeneration of articular cartilage in OA. In the previous studies, we
have focused on nanocarbon molecule, fullerene (C60), which acts a
strong free radical scavenger, as an anti-oxidative agent, to protect
against the OA relating catabolic stress-induced degeneration of artic-
ular cartilage both in vitro and in vivo OA models. We postulated that
C60 may have a potential to protect against the catabolic process of
articular cartilage through the mechanism involving the activation of
Ogg1 in osteoarthritic chondrocytes.
Purpose: 1) The aim of the study was to examine the potential
involvement of accumulation of 8-oxoguanine and impairment of DNA
repair enzyme Ogg1 in the pathogenesis of OA.
2) Secondly, we studied whether or not C60 induced the expression and
activation of Ogg1 in chondrocytes and protect against the down-reg-
ulation of OA chondrocytes and degeneration of articular cartilage in
vitro and in vivo.
Methods: 8-Oxoguanine and Ogg1 expressions were immunohistoro-
gically investigated in articular cartilages from patients with OA and
from OA model rabbits. We studied whether OA-relating catabolic
factors, IL-1beta (10 ng/ml) and H2O2 (100 mM), induced Ogg1 expres-
sion in OA chondrocytes. Knockdown of Ogg1 was also performed to
investigatewhether Ogg1 and C60were associatedwith cellular activity
and survival in human chondrocytes in vitro.
Results: The increased level of 8-oxoguanine and decreased level of
Ogg1 in osteoarthritic chondrocytes of degenerated cartilage were
observed in comparison with chondrocytes of intact cartilage in animal
models of OA and in patients with OA. We also found that over-
expression of Ogg1 in human osteoarthritis chondrocytes prevented
Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489 S167oxidant-induced mitochondrial dysfunction, OA relating catabolic
stress-induced caspase-9 activation and apoptosis in vitro. Furthermore,
Ogg1 silencing using siRNA reduced chondrocyte activity and augments
apoptosis in human chondrocytes. Treatment with C60 fullerene
induced the expression of Ogg1 and maintained its functions in
osteoarthritic chondrocytes even in the presence of OA relating catab-
olic factors.
Conclusion: Our recent study revealed the potential involvement of
accumulation of 8-Oxoguanine, an oxidized form of guanine, and
impairment of DNA repair enzyme Ogg1 in the pathogenesis of OA,
suggesting that Ogg1 prevents catabolic stress-mediated chondrocyte
dysfunction and apoptosis that might be important in the maintenance
of articular cartilage. C60 fullerene may have a therapeutic potential to
protect against the degeneration of articular cartilage through the
activation of Ogg1 in OA chondrocytes.
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CHONDROCYTE DEDIFFERENTIATION: ACTIN REGULATES THE
PASSAGED CELL PHENOTYPE THROUGH MRTFA
J. Parreno, S. Raju, A. Jiang, K. Andrejevic, R.A. Kandel. Lunenfeld-
Tanenbaum Res. Inst., Toronto, ON, Canada
Purpose: Articular cartilage when damaged is incapable of self-repair
and degeneration progresses to the point where joint replacement is
necessary. Autologous cell based repair of articular cartilage is a
promising therapy. While the US Food and Drug Administration has
approved the clinical use of chondrocytes that have been expanded in
vitro to obtain larger number of cells, cells cultured using traditional 2D
monolayer conditions undergo a phenotypic shift in a process termed
dedifferentiation. Passaged (dedifferentiated) cells are larger, spread
and acquire actin stress ﬁbers. They express ﬁbroblastic matrix (such as
type I collagen; COL1A1) as well as contractile (alpha smooth muscle
actin; aSMA) molecules resulting in biomechanically inferior tissue
capable of shrinkage. The study aim was to further characterize the
dedifferentiation process and gain insight into the molecular mecha-
nism regulating dedifferentiation. In particular, while actin depolyme-
rization has been shown to enhance the chondrogenic phenotype of
cells, the mechanisms downstream of actin leading to gene regulation
has not been fully elucidated. In other cell types actin depolymerization
has been shown to result in binding of myocardin related transcription
factor (MRTFa) to globular units of actin thereby removing MRTFa from
the nucleus where it acts as a coactivator of serum response factor (SRF).
Since MRTFa/SRF activation has been shown to regulate Col1A1 and
aSMA expression, and as these are expressed in passaged cells, we
hypothesized that passaged cells have a higher proportion of poly-
merized actin and nuclear MRTFa then primary chondrocytes. Actin
depolymerization or MRTFa/SRF inhibition should repress dediffer-
entiated molecule expression and promote a redifferentiated
phenotype.
Methods: Cell phenotype was initially characterized in terms of: mor-
phology through measurement of cell area and circularity; actin
organization through immunostaining with phalloidin-alexa 598 con-
jugate and assessment of globular-to-ﬁlamentous (g-/f-) actin ratio
through triton-solubility fraction separation followed by western blot;
MRTFa localization through immunocytochemistry and nuclear/cyto-
plasmic separation followed by western blot; expression of chondro-
genic, ﬁbroblastic, and contractile genes through real-time RT-PCR;
ﬁbroblastic and contractile molecule protein levels through western
blot analysis; and functional cell contraction assessment through
stress-relaxation of cell-embedded collagen gels.
Results: As compared to primary chondrocytes, passaged twice (P2)
cells were larger, less circular, developed actin stress ﬁbers, exhibited
lower g-/f-actin, and displayed a larger proportion of MRTFa within the
nucleus of cells (ﬁg.1). P2 cells had elevated expression levels of SRF-regulated ﬁbroblastic matrix and contractile molecules. Further, P2 cells
acquired the ability to contract stress-relaxed type I collagen gels.
Exposure of passaged cells to the actin depolymerization agent,
latrunculin B, resulted in decreased cell area, increased circularity, loss
of actin stress ﬁbers, increased g-/f-actin, higher cytoplasmic pro-
portion of MRTFa, repressed SRF-regulated gene expression, and
diminished ability to contract collagen gels. Cells exposed toMRTFa/SRF
inhibitor (CCG1423) still exhibited actin stress ﬁbers, however had
elevated g-/f-actin and cytoplasmic localization of MRTFa. Silencing of
MRTFa/SRF repressed speciﬁc dedifferentiated gene levels (ﬁg.2) as well
as decreased the ability of cells to contract collagen gels.
Conclusion: Actin polymerization activates the MRTFa/SRF pathway
and is responsible for the acquisition of the dedifferentiated phenotype
of passaged cells. Further, this study demonstrates that MRTFa/SRF
repression may be required in order to develop non-contractile, non-
ﬁbroblastic tissue by passaged cells. Understanding the process implicit
in dedifferentiation can facilitate development of methodology to
generate fully functional bioengineered articular cartilage tissue.
Figure 1. Confocal analysis of P0 and P2 cells þ/- drug treatment. MRTFa
(green) actin (phallodin; red) and nuclei (DAPI; blue). Scale bar 10mm
Figure 2. mRNA levels for (A) Col1a1 and (B) aSMA in P0 or P2 cells in the
presence or absence of the MRTF inhibitor, CCG14423. *p < 0.001 com-
pared to P2 control
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LONGITUDINAL ANALYSIS OF PRIMARY HUMAN ARTICULAR
CHONDROCYTE TRANSCRIPTOMIC REGULATION BY INTERLEUKIN
1b UNDER HYPEROSMOTIC CONDITIONS
S.R. Tew, B.T. McDermott, P.D. Clegg. Univ. of Liverpool, Liverpool, United
Kingdom
Purpose: The inﬂammatory cytokine interleukin-1b is known to induce
increased extracellular matrix turnover and reduced synthesis in
articular cartilage. Many studies have used this cytokine as an in vitro
model for cartilage turnover. On the whole, these investigations are
conducted using standard cell culture media with an osmolarity of
around 320mOsm. However the osmolarity that chondrocytes are
exposed to in vivo is generally much higher than this. This project
examines the how chondrocytes respond over a 24 hour period to
interleukin-1b stimulation and whether the osmotic environment
attenuates this response.
